Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
121 hedge funds and large institutions have $535M invested in Endocyte, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 35 increasing their positions, 34 reducing their positions, and 11 closing their positions.
282% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 11
183% more capital invested
Capital invested by funds: $189M → $535M (+$346M)
34% more funds holding
Funds holding: 90 → 121 (+31)
3% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less call options, than puts
Call options by funds: $26.2M | Put options by funds: $28.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.1M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$9.71M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.98M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$5.38M |
| 5 |
Barclays
London,
United Kingdom
|
+$4.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$8.16M |
| 2 |
PA
Perceptive Advisors
New York
|
-$3.43M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.21M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$2.85M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$2.61M |
ECYT Hedge Fund Activity: Q1 2014 in Review
121 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2014, worth a combined $535M — up 183% from $189M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ECYT positions and 11 closed out — a net gain of 31 holders — while 35 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $37.1M. The largest seller was Austin W. Marxe & David M. Greenhouse, cutting an estimated $8.16M.
- 121 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2014, up from 90 in Q4 2013.
- Funds reported $535M of Endocyte, Inc. Common Stock stock for Q1 2014, up 183% quarter-over-quarter.
- 42 funds opened new Endocyte, Inc. Common Stock positions in Q1 2014 and 11 closed out, a net change of +31 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q1 2014 was Fidelity Investments, an estimated $37.1M added.
- The largest Endocyte, Inc. Common Stock seller in Q1 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $8.16M sold.
Based on aggregated 13F filings for Q1 2014.